OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients.

Date publication

janvier 2022

Journal

BMC cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle , Dr BERTAUT Aurélie , Dr BOIDOT Romain , Dr GENNE Philippe , Dr GOBBO Jessica , Dr DESMOULINS Isabelle

Tous les auteurs :
Vachenc S, Gobbo J, Moujarrebe SE, Desmoulins I, Gilabert M, Beau-Faller M, Mitry E, Girard N, Bertaut A, Dusetti N, Iovanna JL, Yousfi R, Pierrat F, Bruno R, Cueff A, Boidot R, Genne P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34991520

Résumé

Nowadays, evaluation of the efficacy and the duration of treatment, in context of monitoring patients with solid tumors, is based on the RECIST methodology. With these criteria, resistance and/or insensitivity are defined as tumor non-response which does not allow a good understanding of the diversity of the underlying mechanisms. The main objective of the OncoSNIPE® collaborative clinical research program is to identify early and late markers of resistance to treatment.

Mots clés

Early/ late resistance marker, Immunological profile, NGS, Non small-cell lung cancer, Pancreatic ductal adenocarcinoma, Triple negative breast or Luminal Breast Cancer

Référence

BMC Cancer. 2022 Jan 6;22(1):41